In addition to defining the diagnosis, the detection of BCR::ABL1 transcripts is essential for the molecular monitoring of patients with CML and assessing their response to tyrosine kinase inhibitor (TKI) treatment [2]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.